Abstract
BackgroundGastro-protective agents (GPA) are co-prescribed with non-steroidal anti-inflammatory drugs (NSAID) to lower the risk of upper gastrointestinal (UGI) events. It is unknown to what extent the protective effect is influenced...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have